Dubinsky RM, et al. (2004, reaffirmed 2008). Practice parameter: Treatment of postherpetic neuralgia. An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 63(6): 959–965.
Other Works Consulted
Centers for Disease Control and Prevention (2008). Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 57(05): 1–30. Also available online: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm. [Erratum in MMWR, 57(28): 779. Also available online: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5728a5.htm.]
Habif TP (2010). Herpes zoster. In Clinical Dermatology, A Color Guide to Diagnosis and Therapy, 5th ed., pp. 479–490. Philadelphia: Mosby.
Herpes zoster vaccine (Zostavax) revisited (2009). Medical Letter on Drugs and Therapeutics, 52(1339): 41.
Strangfeld A, et al. (2009). Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-a agents. JAMA, 301(7): 727–744.
Wolff K, Johnson RA (2009). Varicella-zoster virus infections. In Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, 6th ed., pp. 837–845. New York: McGraw-Hill Medical.
|By:||Reference Healthwise Staff||Last Revised: Reference June 5, 2012|
|Medical Review:||Reference Anne C. Poinier, MD - Internal Medicine
Reference Nancy Ann Shadick, MD, MPH - Internal Medicine, Rheumatology